Effects of CXCR1/2 Blockade with Ladarixin on Streptozotocin-Induced Type 1 Diabetes Mellitus and Peripheral Neuropathy and Retinopathy in Rat (Diabetes Metab J 2025;49:990-1005) Authors: Serena Boccella, Andrea Maria Morace, Cristina Giorgio, Francesca Guida, Michela Perrone, Iolanda Manzo, Carmela Belardo, Meghan Jones, Sabatino Maione, Andrea Aramini, Marcello Allegretti, Livio Luongo, Laura Brandolini Published: 2026 We are pleased to submit the revised version of our manuscript entitled ‘Effects of CXCR1/2 blockade with ladarixin on streptozotocin-induced type 1 diabetes mellitus and peripheral neuropathy and retinopathy in rat’ for consideration in Diabetes & Metabolism Journal [1]. We sincerely thank the reviewers and Dr. Sheng Chen for their thoughtful and insightful comments regarding our study. We have carefully considered the suggestions and have provided detailed responses in our accompanying point-by-point reply. Specifically, we have addressed the questions concerning: 1. Differential regulation of CXC motif chemokine receptor 1/2 (CXCR1/2): We acknowledge the importance of distinguishing receptor-specific effects in the diabetic retina. While the current dataset does not allow definitive conclusions, we have emphasized the need for future cell-type–specific analyses and clarified this in the manuscript discussion. 2. Dose–response analyses and nerve fiber specificity: We agree that translational interpretation requires functional assessments of small versus large nerve fibers. We have highlighted plans for future studies incorporating advanced ocular imaging (e.g., optical coherence tomography angiography) and electrophysiological testing to assess functional outcomes. We believe these revisions strengthen the manuscript and clarify the clinical relevance and potential mechanistic insights of ladarixin in diabetic complications. We appreciate the constructive guidance provided, which has been invaluable in refining our discussion and the presentation of our findings. We hope the revisions meet the expectations of the reviewers and the editorial team and look forward to your favorable consideration. Thank you for your time and attention. Footnotes CONFLICTS OF INTEREST Serena Boccella, Cristina Giorgio, Andrea Aramini, Marcello Allegretti, Meghan Jones, and Laura Brandolini are Dompé Farmaceutici SpA employees and Andrea Maria Morace, Francesca Guida, Michela Perrone, Iolanda Manzo, Carmela Belardo, Sabatino Maione, and Livio Luongo are University of Vanvitelli in Naples employees. The authors declare no competing interests in relation to the contents of this work. The authors declare that this study received funding from Dompé Farmaceutici SpA. REFERENCES